Figure 2.

Forest plot for 24-week sustained modified Multiple Sclerosis Functional Composite progression for daclizumab beta versus IM IFN beta-1a by baseline demographics and disease characteristics.

CI: confidence interval; EDSS: Expanded Disability Status Scale; Gd⁺: gadolinium-enhancing; IFN: interferon; IM: intramuscular; MS: multiple sclerosis; SC: subcutaneous.

^aMissing baseline Gd⁺ lesions data: IM IFN beta-1a, n = 13; daclizumab beta, n = 19.

^bMissing baseline T2 hyperintense lesion volume data: IM IFN beta-1a, n = 14; daclizumab beta, n = 19.

^cMissing baseline disease activity data: IM IFN beta-1a, n = 5; daclizumab beta, n = 12.